ERBB2 and breast cancer: Indeed, Sobo-Vujanovic et al. and our own work demonstrated that sTNFα blockade prevents chemical induced skin carcinogenesis and overcomes trastuzumab resistance in HER2-positive breast cancer models, respectively (71, 151).